526 related articles for article (PubMed ID: 17008693)
1. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.
Dilts DM; Sandler AB
J Clin Oncol; 2006 Oct; 24(28):4545-52. PubMed ID: 17008693
[TBL] [Abstract][Full Text] [Related]
2. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
Dilts DM; Sandler AB; Baker M; Cheng SK; George SL; Karas KS; McGuire S; Menon GS; Reusch J; Sawyer D; Scoggins M; Wu A; Zhou K; Schilsky RL;
J Clin Oncol; 2006 Oct; 24(28):4553-7. PubMed ID: 17008694
[TBL] [Abstract][Full Text] [Related]
3. Variation in institutional review board responses to a standard, observational, pediatric research protocol.
Mansbach J; Acholonu U; Clark S; Camargo CA
Acad Emerg Med; 2007 Apr; 14(4):377-80. PubMed ID: 17312334
[TBL] [Abstract][Full Text] [Related]
4. Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic.
Wang-Gillam A; Williams K; Novello S; Gao F; Scagliotti GV; Govindan R
J Clin Oncol; 2010 Aug; 28(24):3803-7. PubMed ID: 20644091
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
6. State payer mandates to cover care in US oncology trials: do science and ethics matter?
Taylor PL
J Natl Cancer Inst; 2010 Mar; 102(6):376-90. PubMed ID: 20197514
[TBL] [Abstract][Full Text] [Related]
7. CT2--the clinical trials control tower: overcoming barriers to opening oncology clinical trials.
Hammond AL; Waller EK; Finkelstein LB
J Clin Oncol; 2007 Apr; 25(10):1288; author reply 1288. PubMed ID: 17401022
[No Abstract] [Full Text] [Related]
8. Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board.
Saginur R; Dent SF; Schwartz L; Heslegrave R; Stacey S; Manzo J
J Clin Oncol; 2008 Mar; 26(9):1479-82. PubMed ID: 18349399
[TBL] [Abstract][Full Text] [Related]
9. Regulatory challenges: lessons from recent West Nile virus trials in the United States.
Jester PM; Tilden SJ; Li Y; Whitley RJ; Sullender WM
Contemp Clin Trials; 2006 Jun; 27(3):254-9. PubMed ID: 16603417
[TBL] [Abstract][Full Text] [Related]
10. Development of cancer cooperative groups in Japan.
Fukuda H
Jpn J Clin Oncol; 2010 Sep; 40(9):881-90. PubMed ID: 20670961
[TBL] [Abstract][Full Text] [Related]
11. Adapting clinical trials networks to promote cancer prevention and control research.
Weiner BJ; McKinney MM; Carpenter WR
Cancer; 2006 Jan; 106(1):180-7. PubMed ID: 16333855
[TBL] [Abstract][Full Text] [Related]
12. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous.
Steensma DP
J Clin Oncol; 2007 Mar; 25(9):1148; author reply 1148-9. PubMed ID: 17369584
[No Abstract] [Full Text] [Related]
13. [Infrastructure of cancer clinical trial cooperative groups in western countries].
Fukuda H
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1144-51. PubMed ID: 10945009
[TBL] [Abstract][Full Text] [Related]
14. A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval.
Greene SM; Geiger AM
J Clin Epidemiol; 2006 Aug; 59(8):784-90. PubMed ID: 16828670
[TBL] [Abstract][Full Text] [Related]
15. Multicentre trials review process by research ethics committees in Spain: where do they stand before implementing the new European regulation?
Dal-Ré R; Ortega R; Morejón E
J Med Ethics; 2005 Jun; 31(6):344-50. PubMed ID: 15923484
[TBL] [Abstract][Full Text] [Related]
16. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.
Buchanan DR; White JD; O'Mara AM; Kelaghan JW; Smith WB; Minasian LM
J Clin Oncol; 2005 Sep; 23(27):6682-9. PubMed ID: 16170176
[TBL] [Abstract][Full Text] [Related]
17. [The role of the Japan Clinical Oncology Group].
Ohe Y; Saijo N
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1127-32. PubMed ID: 10945006
[TBL] [Abstract][Full Text] [Related]
18. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
Zon R; Meropol NJ; Catalano RB; Schilsky RL
J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967
[TBL] [Abstract][Full Text] [Related]
19. Medical education research and IRB review: an analysis and comparison of the IRB review process at six institutions.
Dyrbye LN; Thomas MR; Mechaber AJ; Eacker A; Harper W; Massie FS; Power DV; Shanafelt TD
Acad Med; 2007 Jul; 82(7):654-60. PubMed ID: 17595560
[TBL] [Abstract][Full Text] [Related]
20. Impact of institutional review board practice variation on observational health services research.
Green LA; Lowery JC; Kowalski CP; Wyszewianski L
Health Serv Res; 2006 Feb; 41(1):214-30. PubMed ID: 16430608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
